Fundraising of €0.25 million by Néovacs

Néovacs, a French company listed on Euronext Growth Paris, announced a fundraising of €0.25 million, carried out by issuing OCEANE-BSA convertible bonds. The financing comes from the European High Growth Opportunities Securitization Fund. This amount will mainly be used to finance the Kinoïde® research program on allergies and to strengthen investments in new projects in biotechnology and medical devices.

Prior to this transaction, Neovacs had already raised €26.6 million through this mechanism, resulting in the creation of more than 24 billion shares. The latest issue could result in the creation of 581,573 new shares. The shares created by this fundraising will mainly be resold on the market, which could put pressure on the share price and dilute shareholders' stake.

The public is encouraged to consider the associated risks, including potential dilution of share value, highlighted in the company's 2021 financial report.